Get access
Clinical Endocrinology

Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients

Authors


Professor Francesco Cavagnini, Chair of Endocrinology, University of Milan, Division of Endocrinology, Ospedale San Luca IRCCS, Istituto Auxologico Italiano, Via Spagnoletto 3, 20149 Milano, Italy. Fax: + 3902619112777; E-mail: cavagnini@auxologico.it

Summary

Objective  Cardiovascular disease is a major contributor to the increased mortality of acromegalic patients. Prolongation of the QT interval is considered an established risk factor for potentially fatal cardiac arrhythmias, an event frequently observed in acromegaly. Changes in ventricular repolarization have been observed with the use of octreotide, one of the somatostatin analogues (SSA) currently used for the medical treatment of this disease. Furthermore, octreotide is listed among the drugs able to prolong the QT interval. Thus, we elected to study the effects of long-term SSA administration on QT duration and left ventricular mass (LVM) in a group of acromegalic patients.

Design and patients  In a retrospective study, 30 acromegalic patients (19 women and 11 men, aged 25–77 years) were studied under basal conditions; 24 of them (15 women and nine men, aged 25–77 years) were studied again after 3–63 months of treatment (median 18 months) with SSA. Twenty-four healthy volunteers served as controls.

Measurements  Patients and controls underwent electrocardiographic (ECG) analysis, and QT interval duration corrected for heart rate (QTc) was established according to the Bazett formula. In 17 of the SSA-treated patients, M- and B-mode echocardiography for the assessment of LVM index (LVMi) was performed.

Results  Baseline QTc was significantly longer in patients than in controls. SSA administration was followed by a significant decrease in QTc, which reached a mean value similar to that measured in the controls. In particular, treatment with SSA normalized QTc in three out of the six patients with abnormally elevated values at baseline. After treatment, a significant reduction in heart rate was recorded, while LVMi displayed a slight but not significant decrease.

Conclusions  Acromegalic patients frequently display an abnormally prolonged QT interval, a known risk factor for potentially fatal arrhythmias. Treatment of these patients with SSA is able to improve and even normalize this alteration, probably contributing to the beneficial effects of these drugs on cardiac rhythm in this endocrine disorder. The inclusion of octreotide in the list of drugs that may increase QTc should be reconsidered as regards its indication in acromegaly.

Get access to the full text of this article

Ancillary